CM
APLS

Castleark Management’s Apellis Pharmaceuticals APLS Stock Holding History

Castleark Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40,820
Closed -$3.72M – 276
2023
Q2 		$3.72M Buy
+40,820
New +$3.52M 0.17% 136
2022
Q4 		– Sell
-57,890
Closed -$3.95M – 284
2022
Q3 		$3.95M Buy
+57,890
New +$3.43M 0.22% 115
2022
Q1 		– Sell
-53,130
Closed -$2.51M – 324
2021
Q4 		$2.51M Buy
+53,130
New +$2.09M 0.09% 177
2020
Q2 		– Sell
-147,165
Closed -$3.94M – 340
2020
Q1 		$3.94M Buy
+147,165
New +$5.22M 0.23% 119

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Castleark Management's APLS Position: Q3 2023 in Review

Castleark Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2023, closing a stake of 40,820 shares — an estimated $3.72M sold.

Castleark Management first reported a position in APLS in Q1 2020 and held it in 4 quarters. The position peaked at $3.95M in Q3 2022. 256 funds tracked by Wall St. Rank hold APLS as of Q3 2023.

  • Castleark Management reported no remaining Apellis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Castleark Management sold 40,820 Apellis Pharmaceuticals shares in Q3 2023, an estimated $3.72M.
  • Castleark Management first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Castleark Management's Apellis Pharmaceuticals position peaked at $3.95M in Q3 2022.
  • 256 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2023.

Based on Castleark Management's 13F filing for Q3 2023, filed 15 Nov 2023.